- Home
- ACET vs DIBS Comparison
ACET vs DIBS Comparison
Compare ACET & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- DIBS
- Stock Information
- Founded
- ACET 1947
- DIBS 2000
- Country
- ACET United States
- DIBS United States
- Employees
- ACET N/A
- DIBS N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- DIBS Catalog/Specialty Distribution
- Sector
- ACET Health Care
- DIBS Consumer Discretionary
- Exchange
- ACET Nasdaq
- DIBS Nasdaq
- Market Cap
- ACET 111.9M
- DIBS 99.7M
- IPO Year
- ACET N/A
- DIBS 2021
- Fundamental
- Price
- ACET $0.64
- DIBS $4.02
- Analyst Decision
- ACET Buy
- DIBS Hold
- Analyst Count
- ACET 4
- DIBS 1
- Target Price
- ACET $8.50
- DIBS N/A
- AVG Volume (30 Days)
- ACET 2.2M
- DIBS 126.4K
- Earning Date
- ACET 11-05-2025
- DIBS 11-07-2025
- Dividend Yield
- ACET N/A
- DIBS N/A
- EPS Growth
- ACET N/A
- DIBS N/A
- EPS
- ACET N/A
- DIBS N/A
- Revenue
- ACET N/A
- DIBS $89,422,000.00
- Revenue This Year
- ACET N/A
- DIBS $2.87
- Revenue Next Year
- ACET N/A
- DIBS $3.26
- P/E Ratio
- ACET N/A
- DIBS N/A
- Revenue Growth
- ACET N/A
- DIBS 3.49
- 52 Week Low
- ACET $0.45
- DIBS $2.30
- 52 Week High
- ACET $1.40
- DIBS $4.38
- Technical
- Relative Strength Index (RSI)
- ACET 31.44
- DIBS 72.47
- Support Level
- ACET $0.66
- DIBS $3.47
- Resistance Level
- ACET $0.71
- DIBS $3.64
- Average True Range (ATR)
- ACET 0.07
- DIBS 0.25
- MACD
- ACET -0.03
- DIBS 0.04
- Stochastic Oscillator
- ACET 7.83
- DIBS 83.16
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.